Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company focused on minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. This news page aggregates company announcements, clinical updates, and financial disclosures so readers can follow how Inspire therapy and the Inspire V system are progressing in clinical practice and the marketplace.
Inspire regularly issues earnings releases and financial guidance, including preliminary and unaudited revenue ranges, full-year outlooks, and discussions of non-GAAP measures such as adjusted net income and adjusted EBITDA. Investors can track how revenue tied to Inspire therapy evolves over time, as well as information about share repurchase authorizations and tax-related items disclosed in Form 8-K filings and accompanying press releases.
Because Inspire’s core business is neurostimulation-based treatment for moderate to severe obstructive sleep apnea, a significant portion of its news flow centers on clinical data and product evolution. The company publishes outcomes from studies of the Inspire V system, including procedure success rates, reductions in disease severity, and patient adherence, and presents these results at medical meetings such as the American Academy of Otolaryngology–Head and Neck Surgery and the International Surgical Sleep Society.
Corporate governance and leadership changes are also covered, including announcements about the transition of the Chief Financial Officer role, executive employment agreements, and retirement plans for senior leaders. In addition, Inspire frequently reports on its participation in major healthcare and investor conferences, where management discusses business performance, reimbursement developments, and strategic priorities.
By reviewing this news feed, followers of INSP stock can see how Inspire communicates its financial performance, clinical evidence, regulatory and reimbursement context, and leadership decisions over time, all drawn from company-issued releases and related SEC filings.
Inspire Medical Systems, Inc. (NYSE: INSP) announced a public offering of 1,000,000 shares at $215.00 each, with an additional 150,000 shares available for purchase by the underwriter. The offering is set to close on August 16, 2022, subject to conditions. Goldman Sachs & Co. LLC is the sole underwriter for this transaction. The shares are offered under an effective shelf registration statement with the SEC, initially filed on April 13, 2020. Funds raised may be utilized for corporate purposes, supporting Inspire's ongoing development in obstructive sleep apnea treatments.
Inspire Medical Systems (NYSE: INSP) announced a public offering of 1,000,000 shares of its common stock, with an option for the underwriter to purchase an additional 150,000 shares. The offering will be conducted through an effective shelf registration statement filed with the SEC. Goldman Sachs & Co. LLC is the sole underwriter. Proceeds from the offering are intended to enhance Inspire's innovative solutions for obstructive sleep apnea treatment. The preliminary prospectus supplement will be filed with the SEC and be available free of charge on their website.
Inspire Medical Systems reported a 73% revenue growth year-over-year for Q2 2022, reaching $91.4 million. The gross margin stood at 84.5%, despite a slight decrease from the previous year due to higher component costs. Inspire activated 52 new centers and created 17 new sales territories, totaling 785 centers and 191 territories. The company received FDA approvals for expanded MRI compatibility and new stimulation leads. Inspire raised its full-year revenue guidance to $354 million to $362 million, reflecting continued positive trends.
Inspire Medical Systems has appointed two new independent directors, Cynthia Burks and Charisse Sparks, M.D., to its board effective July 28, 2022. Burks, former Chief Human Resources Officer at Genentech, brings extensive expertise in human capital strategy, while Dr. Sparks, Chief Medical Officer of AppliedVR, offers significant experience in medical device R&D and regulatory affairs. These additions aim to strengthen Inspire's leadership and support its mission in developing innovative solutions for obstructive sleep apnea.
Inspire Medical Systems (NYSE: INSP) announced FDA approval for additional MRI scan conditions for its Inspire therapy, expanding from head, neck, and extremity scans to full-body MRIs. This retroactive approval applies to all patients using the Inspire IV neurostimulator since its 2018 launch. CEO Tim Herbert emphasized that this milestone will alleviate concerns for patients regarding future MRI access, thereby enhancing treatment options for those suffering from obstructive sleep apnea. The therapy is recognized as the only FDA-approved neurostimulation technology for this condition.
Inspire Medical Systems (NYSE: INSP) will announce its financial results for Q2 2022 on August 2, after market hours. A conference call is scheduled for 5:00 p.m. ET to discuss these results and recent business developments. The call can be accessed through a registration link, and a simultaneous webcast will be available on Inspire's Investor Relations page. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, notably its FDA-approved Inspire therapy, which offers treatment for moderate to severe cases.
Inspire Medical Systems (NYSE: INSP) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 7:00 p.m. Eastern Time. The event will take place at the Terranea Resort in Rancho Palos Verdes, CA, with a live webcast accessible at this link. A replay will be available for two weeks on Inspire's Investor website. The company specializes in innovative, minimally invasive treatments for obstructive sleep apnea, including the FDA-approved Inspire therapy, the first neurostimulation technology for this condition.
Inspire Medical Systems announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 1:00 p.m. Eastern Time. The presentation will focus on Inspire's innovative solutions for obstructive sleep apnea, including its proprietary FDA-approved neurostimulation therapy. Attendees can access the live webcast and a replay of the event, which will be available for two weeks afterwards on Inspire's Investor website.
Inspire Medical Systems is showcasing its innovations at the SLEEP 2022 conference from June 4-8, highlighting the Inspire SleepSync™ digital health platform enabled by a new Bluetooth® remote. The platform now encompasses over 2.5 million nights of sleep data. The company will host an educational symposium on optimizing patient outcomes with Inspire therapy and participate in key scientific sessions discussing upper airway stimulation therapy. Inspire aims to demonstrate its commitment to advancing sleep apnea treatment with interactive physician discussions.
Inspire Medical Systems (NYSE: INSP) announced its management team will present at the UBS Global Healthcare Conference on May 25, 2022, at 1:15 p.m. ET in New York. The presentation will focus on Inspire's innovative, minimally invasive solutions for obstructive sleep apnea, including its FDA-approved neurostimulation technology, Inspire therapy. A live webcast will be available for those unable to attend in person, with a replay accessible for two weeks post-event on Inspire’s investor website.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
